1-6 of 6
Umang Swami
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Open Access
Chadi Hage Chehade, Ryon P. Graf, Zeynep Irem Ozay, Georges Gebrael, Nicolas Sayegh, Gerald Li, Benjamin L. Maughan, Emmanuel S. Antonarakis, Rana R. McKay, Neeraj Agarwal, Umang Swami
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF9.
https://doi.org/10.1158/1078-0432.CCR-25-1178
Published: 01 July 2025
View articletitled, Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Open the PDF for Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma

Available to Purchase
Yousef Zakharia, Ryan J. Reis, Matthew R. Kroll, Aseel O. Rataan, Srija Manchkanti, Bilal Rahim, Rohan Garje, Umang Swami, Sarah L. Mott, K.D. Zamba, Jessica C. Sieren, Aliasger K. Salem, Youcef Rustum
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (7): 1204–1211.
https://doi.org/10.1158/1078-0432.CCR-24-3234
Published: 01 April 2025
View articletitled, Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
Open the PDF for Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer

Available to Purchase
Yohann Loriot, Arjun V. Balar, Daniel P. Petrylak, Arash R. Kalebasty, Petros Grivas, Aude Fléchon, Rohit K. Jain, Umang Swami, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, Mitch Sierecki, Marianna Zavodovskaya, Emon Elboudwarej, Lauri Diehl, Juliane M. Jürgensmeier, Scott T. Tagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3179–3188.
https://doi.org/10.1158/1078-0432.CCR-23-3924
Published: 01 August 2024
View articletitled, Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Open the PDF for Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer in another window
Includes: Supplementary data
Journal Articles

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

Available to Purchase
Umang Swami, Ryon P. Graf, Roberto H. Nussenzveig, Virginia Fisher, Hanna Tukachinsky, Alexa B. Schrock, Gerald Li, Jeffrey S. Ross, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Geoffrey R. Oxnard, Emmanuel S. Antonarakis, Neeraj Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4917–4925.
https://doi.org/10.1158/1078-0432.CCR-22-2228
Published: 14 November 2022
View articletitled, SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Open the PDF for SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Quest for Ideal Composite Biomarkers for Response to Immunotherapies

Available to Purchase
Umang Swami, Roberto H. Nussenzveig, Neeraj Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5059–5061.
https://doi.org/10.1158/1078-0432.CCR-20-2321
Published: 01 October 2020
View articletitled, Quest for Ideal Composite Biomarkers for Response to Immunotherapies
Open the PDF for Quest for Ideal Composite Biomarkers for Response to Immunotherapies in another window
Journal Articles

Abstract B23: A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi), in advanced soft tissue sarcomas (STS)

Free
Umang Swami, Varun Monga, Munir Tanas, Aaron Bossler, Sarah Mott, Brian Smith, Mohammed Milhem
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2_Supplement): B23.
https://doi.org/10.1158/1557-3265.SARCOMAS17-B23
Published: 15 January 2018
View articletitled, Abstract B23: A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi), in advanced soft tissue sarcomas (STS)